Loading…
← CockpitCompetitor Analysis › 4174.TWO OBI Pharma, Inc.Open in the cockpit ↗

OBI Pharma, Inc.4174.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Pharmaceuticals: Major
Momentum leader 100
Mkt cap
$295M
US dollars, full cap
Free float
86%
of shares outstanding
$/day
$2.47M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-54.8 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
117 days
15 Mar 2027
Close · TWDNT$77.50
1D-1.1%
1W+40.9%
1M+29.4%
3M+189.7%
6M+134.8%
YTD+43.5%
1Y+46.5%
ATR %6.2%
52w lowhigh6.6% off high

What OBI Pharma does

No business profile yet.

OBI Pharma at a glance

Size OBI Pharma (4174.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $295M, the 641st largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$77.50 on 18 Nov 2026.

Performance Over six months the shares gained 134.8%, against -22.8% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue fell 2.2% over the last twelve months (peer median +2.9%); the operating margin is -2,968.3% (peer median 3.7%).

Valuation It trades at 214.0× enterprise value to sales against a peer median of 4.1× (2nd most expensive of 19).

Capital Return on invested capital runs 54.8 points below its cost of capital (5.0% WACC).

Next results Next results expected around 15 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020025021 May 202621 Aug 202618 Nov 20264174.TWO 238Peer median 76
Six months, rebased to 100: OBI Pharma against the median of its 20 peers (local-currency closes).

OBI Pharma financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$48.2MNT$58.6MNT$62.7MNT$41.5MNT$4.71M
Revenue growth—-7%+51%+782%—
Gross profit-NT$281M-NT$305M-NT$299M-NT$322M-NT$287M
EBITDA-NT$1.23B-NT$1.94B-NT$2.15B-NT$1.84B-NT$1.88B
Net income-NT$1.30B-NT$2.05B-NT$2.31B-NT$1.05B-NT$1.61B
Free cash flow-NT$1.36B-NT$2.06B-NT$1.95B-NT$1.75B-NT$1.87B
Capital expenditureNT$20.9MNT$48.3MNT$120MNT$108MNT$301M
Total debtNT$421MNT$516MNT$505MNT$501MNT$247M

Quarterly statements and history in the cockpit →

OBI Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%0%+20%605199603079300583300086RLMD688302301331ALEMBICLTDINDSWFTLABINO368AAVIR00525017204174.TWO6-month return →1-month return →
Up and to the right = strong over both horizons. OBI Pharma is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×500×605199603079300583688302000790INDSWFTLABINO4174.TWORevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. OBI Pharma is the large dot.

OBI Pharma competitors and peer comparison

How OBI Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

OBI Pharma against its 20 peers (data as of 18 Nov 2026)
Measure4174.TWOPeer medianRank in peer set
1-month return+29.4%-9.7%2nd highest of 21
6-month return+134.8%-22.8%2nd highest of 21
Distance from 52-week high-6.6%-38.0%2nd highest of 21
Revenue growth (TTM)-2.2%+2.9%7th lowest of 19
Operating margin-2,968.3%3.7%2nd lowest of 19
EV / Sales214.0×4.1×2nd most expensive of 19
ROIC minus cost of capital-54.8 pp-7.0 pp2nd lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
OBI Pharma 4174.TWOTaiwan$295M+135%-2%-2,968%214.0×n/an/a
Hainan Huluwa Pharmaceutical 605199.SSChina$296M-21%-32%-58%4.8×1.4%-4.9%
Zhejiang Shengda Bio-Pharm 603079.SSChina$297M-30%-3%7%2.3×4.6%-0.3%
Shandong Sito Bio-technology 300583.SZChina$292M-30%+19%6%2.3×1.6%+2.3%
Honz Pharmaceutical 300086.SZChina$299M-40%-23%-54%7.3×56.0%-12.8%
Relmada Therapeutics RLMDUnited States$305M-60%n/an/an/an/an/a
Hinova Pharmaceuticals 688302.SSChina$305M-35%+251%-195%17.1×n/an/a
Enwei Pharmaceutical 301331.SZChina$308M-20%-7%5%2.1×14.0%+7.3%
Alembic ALEMBICLTD.NSIndia$309M+25%-5%26%13.0×44.3%+26.7%
Chengdu Huasun Technology 000790.SZChina$312M-20%-36%-57%5.6×27.5%-6.4%
Ind-Swift Laboratories INDSWFTLAB.NSIndia$314M+150%+66%9%3.4×n/an/a
Inovio Pharmaceuticals INOUnited States$317M+37%+64%-25,954%921.6×n/an/a
Kitazato 368A.TJapan$317M+7%+9%52%3.1×-16.8%+5.4%
Atea Pharmaceuticals AVIRUnited States$320M-5%n/an/an/an/an/a
GC Corp. 005250.KSSouth Korea$321M-45%+2%3%1.1×n/an/a
Swedencare SECARE.STSweden$321M-24%+3%7%1.8×6.1%+62.1%
Foresee Pharmaceuticals 6576.TWOTaiwan$322M-12%+6%-104%21.4×n/an/a
Beihai Gofar Chuanshan Biological 600538.SSChina$326M-39%+10%-8%6.2×n/an/a
Chongqing Hifuture Information Technology 002168.SZChina$326M-27%+2%-6%7.4×14.3%-14.0%
Standard Chemical & Pharmaceutical 1720.TWTaiwan$329M-1%+5%22%1.8×-11.5%+10.3%
Kingchem (Liaoning) Life Science 301509.SZChina$333M-28%+3%6%1.4×9.2%+6.5%

Questions

Which companies are OBI Pharma's closest peers?
The cockpit's peer set: Hainan Huluwa Pharmaceutical (605199.SS), Zhejiang Shengda Bio-Pharm (603079.SS), Shandong Sito Bio-technology (300583.SZ), Honz Pharmaceutical (300086.SZ), Relmada Therapeutics (RLMD), Hinova Pharmaceuticals (688302.SS), Enwei Pharmaceutical (301331.SZ), Alembic (ALEMBICLTD.NS).
Is OBI Pharma expensive compared with its peers?
On ev / sales it trades at 214.0× against a peer median of 4.1×, 2nd most expensive of 19 in its peer set.
How has OBI Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned +134.8% against -22.8% for the median peer; over one year +46.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.